Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference

Rhea-AI Summary

Verrica Pharmaceuticals Inc. will participate in a fireside chat at the TD Cowen 44th Annual Healthcare Conference in Boston, Massachusetts on March 5, 2024. Investors can access a live webcast of the event on the Verrica website.

WEST CHESTER, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that they will participate in a fireside chat at the TD Cowen 44^th Annual Healthcare Conference, which will be held in Boston, Massachusetts.

Event details:
Date: Tuesday, March 5, 2024
Time: 10:30am ET
Location: Boston, MA

Participants may access a live webcast of the event by clicking the link here.

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.

About Verrica Pharmaceuticals Inc. 
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. On July 21, 2023, Verrica’s lead product, YCANTH (cantharidin), became the first treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. VP-102 is also in development to treat common warts and external genital warts, two of the largest remaining unmet needs in medical dermatology since YCANTH’s approval. Verrica is developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

Terry Kohler 
Chief Financial Officer 
tkohler@verrica.com

Kevin Gardner 
LifeSci Advisors 
kgardner@lifesciadvisors.com

Chris Calabrese 
LifeSci Advisors 
ccalabrese@lifesciadvisors.com

When is Verrica Pharmaceuticals participating in the TD Cowen 44th Annual Healthcare Conference?

Verrica Pharmaceuticals is participating on March 5, 2024.

Where will the conference be held?

The conference will be held in Boston, Massachusetts.

How can investors access the live webcast of the event?

Investors can access the webcast on the Verrica website or by clicking the provided link.

For how long will the webcast be available for replay?

The webcast will be available for replay for 90 days following the event.